Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Brar on the Need to Identify Biomarkers in HCC

October 19th 2020

Gagandeep Brar, MD, discusses the need to identify biomarkers in hepatocellular carcinoma.

DisTinGuish Trial Doses First Patient With Investigational Dickkopf-1 Antibody DKN-01 Plus Tislelizumab in Gastric/GEJ Cancer

October 19th 2020

The first patient has officially been dosed with investigational anti-Dickkopf-1 antibody plus tislelizumab with or without chemotherapy as part of the ongoing phase 2a DisTinGuish study (NCT04363801) in patients with gastric or gastroesophageal junction cancer.

Dr. Sun on First-Line Treatment Challenges in Gastric Cancer

October 16th 2020

Weijing Sun, MD, FACP, discusses remaining challenges in the first-line treatment of patients with gastric cancer.

Nivolumab Nears EU Approval for Second-Line Esophageal Squamous Cell Carcinoma

October 16th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for nivolumab in the treatment of adult patients with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma following previous fluoropyrimidine- and platinum-based chemotherapy.

Ongoing Studies Could Modify the Script in Metastatic Pancreatic Cancer

October 15th 2020

Allyson Ocean, MD, discussed the importance of clinical trials and how they should not be viewed as a last resort for patients with metastatic pancreatic cancer.

Optimized Sequencing Remains a Top Priority in HCC

October 13th 2020

Gagandeep Brar, MD, discusses how the treatment paradigm has expanded in hepatocellular carcinoma, continuing sequencing challenges, and ongoing trials that are expected to impact the landscape.

First-in-Human T-Cell Therapy Warrants Further Investigation in HCC

October 9th 2020

New data showing efficacy and tolerability with ADP-A2AFP, alpha-fetoprotein–directed specific peptide enhanced affinity receptor T-cells, suggest that further research evaluating the 5 billion or more cell dosing regimen is warranted in hepatocellular carcinoma.

Bavituximab/Pembrolizumab Combo Is Active in Advanced Gastric/GEJ Cancer

October 6th 2020

The combination of bavituximab and pembrolizumab demonstrated synergistic antitumor activity and was well tolerated in patients with pretreated advanced gastric or gastroesophageal junction cancer.

Onvansertib Plus FOLFIRI/Bevacizumab Shows Early Efficacy, Safety in KRAS-Mutated mCRC

October 5th 2020

The combination of onvansertib plus with 5-fluorouracil, FOLFIRI, and bevacizumab was shown to have preliminary efficacy with acceptable safety when used as a second-line treatment for patients with KRAS-mutated metastatic colorectal cancer.

New and Emerging Targeted Therapies Show Promise in Biliary Tract Cancer

October 4th 2020

Molecular profiling has led to a better understanding of biliary tract cancers by revealing new markers that can be targeted by novel therapies, and several are currently under investigation.

XmAb18087 Shows Encouraging Preliminary Activity in NETs

October 3rd 2020

XmAb18087 demonstrated a disease control rate of 43% across dose levels in patients with neuroendocrine tumors and a favorable safety profile.

Novel Somatostatin Analog Shows Early Activity in Metastatic NETs, Irrespective of Primary Tumor Site

October 3rd 2020

The novel somatostatin analog for the Targeted Alpha-emitter Therapy 212Pb-DOTAMTATE has demonstrated early efficacy and a tolerable safety profile in a small cohort of patients with metastatic somatostatin receptor–expressing neuroendocrine tumors irrespective of location of the primary tumor.

Dr. Chauhan on Key Recent Advances in Neuroendocrine Tumors

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses key recent advances in therapeutics for patients with neuroendocrine tumors, and points to the future with ongoing combination studies.

Increased Lanreotride Autogel Dosing Shows Encouraging Antitumor Activity in Progressive Pancreatic, Midguts NETs

October 3rd 2020

Increasing the dosage of lanreotide autogel from every 28 days to every 14 days led to encouraging progression-free survival outcomes in patients with progressive pancreatic and midgut neuroendocrine tumors.

Dr. Strosberg on Retreatment With Lutathera in Advanced NETs

October 3rd 2020

Jonathan Strosberg, MD, discusses retreatment with Lutathera in advanced neuroendocrine tumors.

Dr. Chauhan on the Role of Lutathera in NETs

October 3rd 2020

Aman Chauhan, MD, a medical oncologist at the University of Kentucky, discusses the role of Lutathera in neuroendocrine tumors.

2020 ISGIO Seeks to Simplify Complexities in GI Cancer to Improve Care

October 3rd 2020

Tanios S. Bekaii-Saab, MD, FACP, shares key topics covered in the 17th Annual ISGIO meeting and its significance in the ever-evolving GI cancer space.

Dual CDK4/6, MEK Blockade Demonstrates Synergy in PNET Models

October 2nd 2020

Combination CDK4/6 and MEK inhibition was “highly synergistic” in killing pancreatic neuroendocrine tumor cells in vitro and effectively suppressed PNET growth in mice.

Dr. Pavel on the PFS With Lanreotide Autogel in the CLARINET FORTE Trial

October 2nd 2020

Marianne Pavel, MD, discusses the progression-free survival of patients with pancreatic and midgut neuroendocrine tumors who are treated with lanreotide autogel in the phase 2 CLARINET FORTE trial.

Lutathera-Based PRRT Retreatment Shows OS Benefit With Acceptable Safety in NETs

October 2nd 2020

Retreatment with Lutathera-based peptide receptor radionuclide therapy has been shown to have an encouraging survival benefit with an acceptable safety in patients with neuroendocrine tumors.